Ulcerative colitis is a type of inflammatory bowel disease that causes long-lasting inflammation and ulcers in the lining of the large intestine. The disease is characterized by abdominal pain, rectal bleeding, and frequent bowel movements. Growing prevalence of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis is driving the demand for effective treatments in the United Kingdom. The disease primarily affects people between the ages of 15 and 30 years but can develop at any age.
The Global United Kingdom Ulcerative Colitis Market Size is estimated to be valued at US$ 421.3 Mn in 2024 and is expected to exhibit a CAGR of 3.4% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the United Kingdom Ulcerative Colitis are AbbVie Inc. (Allergan, Inc.), Merck & Co., Inc., Novartis AG, Bausch Health Companies Inc., Johnson & Johnson and Among Others. Growing disease prevalence in the United Kingdom has increased the demand for effective drugs to manage symptoms of ulcerative colitis. According to the World Health Organization, over 1 million people in the UK have ulcerative colitis or Crohn’s disease. Introduction of novel biologics and pipeline drugs are expected to provide new treatment options and drive market growth over the forecast period. Advancements in drug delivery systems such as injectables and infusion are transforming ulcerative colitis treatment landscape.
Market Trends
Increasing Research Investments In Novel Drug Formulations: Major pharmaceutical companies are increasing investments for development of novel formulations such as delayed and controlled release preparations, injectables and infusions to improve treatment effectiveness and convenience in ulcerative colitis. This is expected to drive the introduction of advanced therapeutics and support market growth.
Rising Demand For Biosimilars: Patent expiries of major biologics is boosting the entry of biosimilar drugs in the United Kingdom ulcerative colitis market. Biosimilars offer cost-effective treatment options and help expand access to biologics, thereby fueling market revenues.
Market Opportunities
Growing research in gut microbiome therapeutics: Several biotechs are conducting clinical research evaluating the role of gut microbiota in disease pathogenesis. Delivery of specific probiotic strains is a promising avenue being explored for management of ulcerative colitis. Success in these programs can lead to approval of novel microbiome-based drugs in the market.
Increasing focus on fecal microbiota transplants: Fecal microbiota transplantation or bacterial transplantation is gaining consideration as an emerging treatment alternative. Ongoing clinical trials investigating safety and efficacy of FMT may lead to new treatment options over the forecast period.
Impact of Covid-19 On United Kingdom Ulcerative Colitis Market
The COVID-19 pandemic has severely impacted the growth of ulcerative colitis market in United Kingdom. The implementation of lockdown and social distancing measures led to closure of hospitals and clinics for non-emergency procedures. This resulted in delay or cancellation of endoscopy and colonoscopy procedures required for ulcerative colitis diagnosis and treatment. Patients also avoided in-person visits to healthcare centers due to fear of virus infection. This adversely affected the new patient identification and treatment initiation over the short term. However, healthcare providers adopted telehealth and telemedicine services to ensure continuity of care. Online consultations and remote prescriptions and delivery of medications helped maintains patients’ treatment adherence during lockdowns. With resumption of healthcare services as lockdowns eased, the market is regaining growth trajectory. However, future waves of virus outbreaks may again pose challenges.
Geographical Regions with Concentrated United Kingdom Ulcerative Colitis Market
The United Kingdom ulcerative colitis market is highly concentrated in England region in terms of value. England accounts for over 80% of the total market value led by high prevalence of disease and accessibility to advanced healthcare facilities in major cities. The concentration is further higher in densely populated areas like South England, London, Birmingham and Manchester. Availability of leading global pharmaceutical companies, advanced treatments, and high spending capacity of patients in these metropolitan areas contribute to market growth. Other regions like Scotland, Wales and Northern Ireland together account for remaining 20% share with variable growth patterns.
Fastest Growing Region in United Kingdom Ulcerative Colitis Market
Northern Ireland is projected to be the fastest growing region in United Kingdom ulcerative colitis market during forecast period. The growth can be attributed to improving healthcare infrastructure and increasing government focus on better access to treatments for chronic conditions like ulcerative colitis. Initiatives towards digitization of healthcare systems and expansion of telehealth services would aid continual care delivery. Growing patient awareness through local advocacy programs and clinical trials evaluating novel therapies also support growth. While starting from a lower base, Northern Ireland market is expected to see strongest CAGR over next few years driven by these determinants. Other regions may see relatively steady growth on back of established market ecosystem.
What Are The Key Data Covered In This United Kingdom Ulcerative Colitis Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the United Kingdom Ulcerative Colitis's growth between 2024 and 2031.
:- Accurate calculation of the size of the United Kingdom Ulcerative Colitis and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- United Kingdom Ulcerative Colitis Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of United Kingdom Ulcerative Colitis vendors
FAQ’s
Q.1 What are the main factors influencing the United Kingdom Ulcerative Colitis?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top United Kingdom Ulcerative Colitis companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the United Kingdom Ulcerative Colitis’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
Get more insights on this topic: https://www.pressreleasebulletin.com/united-kingdom-ulcerative-colitis-market-trend-size-and-demand-2/
